Second generation tyrosine kinase inhibitor (TKI) that irreversibly inhibits human epidermal receptor 2 (Her2 or ErbB 2) and EGFR (HER1) kinases. An investigational drug for breast cancer as well as other EGFR and Her2 driven cancers such as NSCLC and Head-and-Neck

1. Solca F  et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343:342-50 (2012). 

2. Ioannou N  et al. Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer 105:1554-62 (2011).